Work

Signals and Noise in Drug Safety Analyses

Year: 2013

Type: editorial

Abstract: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance In this issue of Diabetes Care, our edito-rial team has decided to “push the en-velope ” by openly addressing a safety issue in drug development and monitor-ing that is gaining interest and provoking controversy. Traditionally, we have not felt it was our charge to comment on moral issues or political decisions related to aspects of medical care or delivery. Rather, it has been our goal and privilege to “survey the current landscape of clini-cal, research, and health care changes” and “to provide the most up-to-date in-formation for our readers ” (1). On one previous occasion we felt it was necessary

Source: Diabetes Care

DOI: 10.2337/dc13-0895

Authors: William T. Cefalu, Julio Rosenstock, Robert R. Henry, Matthew Riddle

Institutions: Pennington Biomedical Research Center, Louisiana State University System, Louisiana State University, Medical City Dallas Hospital, University of California San Diego, Oregon Health & Science University

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W1984635549

Cites: 6

Cited by: 9

Related to: 10